Absci Corporation

NasdaqGS:ABSI 株式レポート

時価総額：US$795.1m

Absci マネジメント

マネジメント 基準チェック /44

Absciの CEO はSean McClainで、 Aug2011年に任命され、 の在任期間は 14.75年です。 の年間総報酬は$ 3.69Mで、 18.7%給与と81.3%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の5.67%を直接所有しており、その価値は$ 45.05M 。経営陣と取締役会の平均在任期間はそれぞれ3年と3.1年です。

主要情報

Sean McClain

最高経営責任者

US$3.7m

報酬総額

CEO給与比率18.71%
CEO在任期間14.8yrs
CEOの所有権5.7%
経営陣の平均在職期間3yrs
取締役会の平均在任期間3.1yrs

経営陣の近況

Recent updates

分析記事 • Apr 04

We Think Absci (NASDAQ:ABSI) Needs To Drive Business Growth Carefully

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Seeking Alpha • Jan 29

Absci Corporation: Drawing Potential Insights On ABS-101 And ABS-201

Summary Absci Corporation leverages AI for drug development, with clinical data already produced by ABS-101 and ahead for ABS-201 in 2026. ABS-101, an anti-TL1A antibody, might have fallen a little short of next-generation competitors in terms of half-life but might have advantages in other indications. ABS-201 has a competitor, HMI-115, that has performed in endometriosis and perhaps androgenetic alopecia. Read the full article on Seeking Alpha
分析記事 • Jul 19

Does Absci (NASDAQ:ABSI) Have A Healthy Balance Sheet?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Seeking Alpha • Jan 13

Absci Looks Cheap And Positioned For Growth With AMD's AI Backing

Summary Absci recently received a $20 million PIPE investment from AMD that improves its runway and R&D platform with AI. ABS-101 appears to be ABSI’s main drug candidate for IBD. However, ABS-201 for hair loss and ABS-301 for solid tumors offer additional sizeable TAMs if successful. ABSI’s AI models and wet lab data seem quite promising for discovering further antibodies that could be highly differentiated from other competitors. ABSI trades at a cheap P/B of 1.5, so I don’t think the shares have priced in the potential of its partnership with AMD yet. My main concern is that ABSI operates with highly speculative technologies, and its candidates remain in the early R&D stages. Read the full article on Seeking Alpha
Seeking Alpha • Nov 20

Absci Corporation: Struggling To Live Up To Its AI Promise

Summary Absci Corporation's stock has rebounded due to new collaborations, but skepticism about AI's impact on drug discovery keeps it heavily underwater from its IPO price. Absci uses AI and wet lab technologies to speed up drug discovery, aiming to reduce preclinical periods to under two years. Despite partnerships with Merck, AstraZeneca, and others, Absci's revenue remains minimal, and it has no advanced pipeline assets yet. With a market cap just over $300 million and cash runway into 1H27, Absci is a speculative play in the AI drug discovery space. An analysis around Absci Corporation follows in the paragraphs below. Read the full article on Seeking Alpha
分析記事 • Nov 13

Is Absci (NASDAQ:ABSI) A Risky Investment?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Seeking Alpha • Oct 29

Absci: Embryonic Pipeline Looks Expensive Relative To Peers

Summary Absci's differentiated drug discovery platform could create significant shareholder value long term. The company has a long and expensive path to traverse before it can prove the merits of its approach though. While cash burn is currently limited, Absci's operations are ramping, meaning increased costs could begin to pressure the share price in the future. Absci has largely avoided the growing pessimism towards AI-enabled drug discovery companies and is beginning to look expensive relative to peers as a result. Read the full article on Seeking Alpha
Seeking Alpha • Oct 03

Absci: AI-Driven Platform Could Establish Best-In-Class TL1A Drug Targeting Profile

Summary Absci Corporation's initiation of a phase 1 study using ABS-101 for the treatment of patients with IBD expected early 2025, with interim data to be released in the 2nd half of 2025. ABS-101 aims to differentiate itself with unique features like de novo antibody creation, multiparameter lead optimization, and reverse immunology, potentially offering superior potency and dosing flexibility. The global Crohn's Disease treatment market is expected to reach $17.80 billion by 2033. The ulcerative colitis treatment market is expected to reach $14.77 billion by 2033. Read the full article on Seeking Alpha
Seeking Alpha • Jul 28

Absci Corporation Leverages AI For Rapid Drug Discovery And Promising Partnerships

Summary Absci Corporation uses IDCP technology to quickly produce high-quality drug candidates in as little as six weeks, reducing costs and improving research success rates. The company has promising candidates in inflammatory bowel disease, dermatology, and immuno-oncology, attracting major partnerships with over $900 million in deal value and royalties. ABSI focuses on three therapeutic areas: inflammatory bowel disease, dermatology, and immuno-oncology. Investors should be aware of the high risks due to the speculative nature of AI-driven drug discovery and potential funding needs. Still, ABSI trades at a reasonable valuation, making it a sound speculative "buy" for investors aware of biotech's inherent risks. Read the full article on Seeking Alpha
分析記事 • Jun 17

Is Absci (NASDAQ:ABSI) A Risky Investment?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Seeking Alpha • May 16

Absci: 'AI' Tag Keeping Company Afloat While Searching For Right Formula

Summary Absci Corporation, an AI-driven drug discovery company, has seen its share price plummet after its IPO in July 2021. Nearly all AI-driven drug discovery companies have struggled with overall share price performance since IPO. Absci's stock has been picking up - +250% across the past six months - thanks to investment in the sector, and a recently agreed partnership with AstraZeneca. Merck is another Big Pharma partner, but these deals don't guarantee revenues and with development programs preclinical, it's difficult to assign much value. Without its "AI" tag, Absci would likely be a $100m - $200m market cap valuation company. The company may show its mettle in time, but the prospect of near term revenues, or further upside, seems remote in 2024. Read the full article on Seeking Alpha
Seeking Alpha • Feb 27

Absci: Differentiated Antibody Discovery Play

Summary Absci combines generative AI with scalable wet lab technologies to improve antibody discovery, with the eventual goal of in silico drug design. While Absci's stock has benefitted from AI hype in recent months, the company has substance. Its approach to antibody drug development is unique and could have advantages. Absci's valuation is still reasonable given the company's long-term potential, but the stock price is likely to be tied to AI sentiment in the near term, creating downside risk. Read the full article on Seeking Alpha

CEO報酬分析

Absci の収益と比較して、Sean McClain の報酬はどのように変化したか？
日付総報酬給与会社業績
Mar 31 2026n/an/a

-US$118m

Dec 31 2025US$4mUS$690k

-US$115m

Sep 30 2025n/an/a

-US$115m

Jun 30 2025n/an/a

-US$113m

Mar 31 2025n/an/a

-US$107m

Dec 31 2024US$10mUS$660k

-US$103m

Sep 30 2024n/an/a

-US$98m

Jun 30 2024n/an/a

-US$92m

Mar 31 2024n/an/a

-US$109m

Dec 31 2023US$3mUS$620k

-US$111m

Sep 30 2023n/an/a

-US$106m

Jun 30 2023n/an/a

-US$112m

Mar 31 2023n/an/a

-US$99m

Dec 31 2022US$4mUS$600k

-US$105m

Sep 30 2022n/an/a

-US$111m

Jun 30 2022n/an/a

-US$107m

Mar 31 2022n/an/a

-US$121m

Dec 31 2021US$4mUS$505k

-US$103m

Sep 30 2021n/an/a

-US$84m

Jun 30 2021n/an/a

-US$73m

Mar 31 2021n/an/a

-US$48m

Dec 31 2020US$1mUS$260k

-US$49m

報酬と市場: Seanの 総報酬 ($USD 3.69M ) は、 US市場 ($USD 3.70M ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Seanの報酬は、過去 1 年間の会社の業績と一致しています。

CEO

Sean McClain (35 yo)

14.8yrs
在職期間
US$3,686,615
報酬

Mr. Sean Mcclain is the Founder of Absci Corporation (formerly known as AbSci, LLC) and serves as its Chief Executive Officer since August 2011 and Director since its formation in October 2020. Mr. Mcclain...

リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Sean McClain
Founder14.8yrsUS$3.69m5.67%
$ 45.1m
Zachariah Jonasson
Chief Business Officer & CFO2.8yrsUS$2.31m0.15%
$ 1.2m
Todd Bedrick
Senior VP & Chief Accounting Officer3.8yrsデータなし0.053%
$ 418.2k
Alexander Khan
CVP of Finance & Head of Investor Relations3.2yrsデータなしデータなし
Shelby Walker
Chief Legal Officer1.9yrsデータなし0.0064%
$ 50.7k
Jeanne Schreuder
Senior Vice President of People & Experienceless than a yearデータなしデータなし
Wen Sha
Chief of Staff4.3yrsデータなしデータなし
Christine Lemke
Senior Vice President of Portfolio & Growth Strategy3.3yrsデータなしデータなし
Amir Shanehsazzadeh
Chief AI Officerless than a yearデータなしデータなし
Ransi Somaratne
Chief Medical Officerless than a yearデータなしデータなし
Amer-Denis Akkad
Vice President of Researchno dataデータなしデータなし
3.0yrs
平均在職期間
51yo
平均年齢

経験豊富な経営陣: ABSIの経営陣は 経験豊富 であると考えられます ( 3年の平均在職年数)。

取締役

名称ポジション在職期間報酬所有権
Sean McClain
Founder5.6yrsUS$3.69m5.67%
$ 45.1m
Mary Szela
Independent Directorless than a yearUS$367.54kデータなし
Karen McGinnis
Lead Independent Director5.8yrsUS$240.10k0.015%
$ 121.5k
François van Houten
Independent Director2.9yrsUS$269.03k0.031%
$ 249.0k
Daniel Rabinovitsj
Independent Director3.5yrsUS$237.60k0.0057%
$ 45.0k
Andreas Busch
Co-Chair of Scientific Advisory Board2.3yrsUS$1.56m0.20%
$ 1.6m
Iain McInnes
Member of Scientific Advisory Board1.5yrsデータなしデータなし
David Goldberg
Member Scientific Advisory Boardless than a yearデータなしデータなし
Menelas Nicolas Pangalos
Independent Director & Member of Scientific Advisory Board2.3yrsUS$245.60k0.11%
$ 897.6k
Joseph Sirosh
Independent Director4.3yrsUS$216.01k0.0057%
$ 45.0k
Victor Greiff
Member of Scientific Advisory Board3.3yrsデータなしデータなし
Hubert Truebel
Member of Scientific Advisory Board3.3yrsデータなしデータなし
3.1yrs
平均在職期間
60yo
平均年齢

経験豊富なボード: ABSIの 取締役会 は 経験豊富 であると考えられます ( 3.1年の平均在任期間)。

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/05/26 10:11
終値2026/05/22 00:00
収益2026/03/31
年間収益2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Absci Corporation 9 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。13

アナリスト機関
Michael RyskinBofA Global Research
Vamil DivanGuggenheim Securities, LLC
null nullGuggenheim Securities, LLC